JPM vs NVG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NVG exhibits a stable Piotroski F-Score of 6/9, but this is overshadowed by severe valuation discrepancies and unsustainable payout metrics. The current price of $12.63 trades at a significant premium to both the Graham Number ($8.87) and the Intrinsic Value ($6.02). Most critically, a payout ratio of 351.11% indicates that dividends are not being covered by earnings, suggesting a reliance on return of capital or leverage. Combined with a 0/100 technical trend and negative revenue growth, the fund appears overvalued and fundamentally fragile.
Compare Another Pair
Related Comparisons
JPM vs NVG: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nuveen AMT-Free Municipal Credit Income Fund (NVG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.